Despite Landfar Bio-medicine's falling price and revenues, i...

Despite Landfar Bio-medicine's falling price and revenues, its high P/S ratio suggests investor optimism. However, inconsistent revenue growth and expected industry growth of 825% may make these prices unsustainable. Without significant medium-term performance improvement, the P/S ratio may decline to a more reasonable level.